Skip to content

LSD research published in 2020

Page 2 of 3: studies 21 to 40 of 52, newest first. Back to the LSD overview

Studies

LSD-induced increases in social adaptation to opinions similar to one’s own are associated with stimulation of serotonin receptors

Scientific Reports July 22, 2020 Patricia Duerler, Leonhard Schilbach, Philipp Stämpfli et al. 36 citations

Abstract Adapting one’s attitudes and behaviors to group norms is essential for successful social interaction and, thus, participation in society. Yet, despite its importance for societal and individual functioning, the underlying neuropharmacology is poorly understood. We therefore investigated its neurochemical and neural correlates in a pharmacological functional magnetic resonance imaging...

21 Psychedelic treatment of functional neurological disorder – a systematic review

Journal of Neurology, Neurosurgery, and Psychiatry July 20, 2020 Matthew Butler, Mathieu Seynaeve, Timothy R. Nicholson et al.

Aims Functional neurological disorder (FND), formerly known as conversion disorder, causes a high burden of disability and distress, and is amongst the most commonly encountered conditions in neurology clinics and neuropsychiatry services, yet the therapeutic evidence base is limited. Research into psychedelics such as psilocybin and lysergic acid diethylamide (LSD) is currently being...

Self-inflicted neck wounds under influence of lysergic acid diethylamide

Medicine July 2, 2020 Brendan Le Daré, Thomas Gicquel, Alain Baert et al. 11 citations

Abstract Rationale: Lysergic acid diethylamide (LSD) is a highly potent psychedelic drug derived from ergot alkaloids. The available literature data derived from controlled studies or usage in a medical setting seem reassuring; however the literature contains very rare cases of fatal self-inflicted injuries associated with LSD exposure. The behavioral disorder that created the conditions...

Development of a Pencil Drawn Paper‐based Analytical Device to Detect Lysergic Acid Diethylamide (LSD)*†

Journal of Forensic Sciences June 30, 2020 Maria Fernanda Muzetti Ribeiro, Fátima Bento, Antônio José Ipólito et al. 22 citations

Abstract The need for agile and proper identification of drugs of abuse has encouraged the scientific community to improve and to develop new methodologies. The drug lysergic acid diethylamide (LSD) is still widely used due to its hallucinogenic effects. The use of voltammetric methods to analyze narcotics has increased in recent years, and the possibility of miniaturizing the electrochemical...

DOI: 10.1111/1556-4029.14494 (opens in new tab) Lysergic acid diethylamide Context archaeology Hair analysis Nanotechnology

Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains

Neuroimage June 30, 2020 Thomas F. Varley, Robin Carhart-Harris, Leor Roseman et al. 91 citations

Psychedelic drugs, such as psilocybin and LSD, represent unique tools for researchers investigating the neural origins of consciousness. Currently, the most compelling theories of how psychedelics exert their effects is by increasing the complexity of brain activity and moving the system towards a critical point between order and disorder, creating more dynamic and complex patterns of neural...

Subjective time under altered states of consciousness in ayahuasca users in shamanistic rituals involving music

Brazilian Journal of Medical and Biological Research June 20, 2020 A.p.s. Campagnoli, L.a.s. Pereira, José Lino Oliveira Bueno 11 citations

Ayahuasca is described as a hallucinogenic substance whose property is to alter the subjective experience of time and impair the perception of the passage of time during stimuli of more than two to three seconds. The dose-dependent effects of two concentrations of ayahuasca in the ritualistic context were investigated employing temporal reproduction tasks in participants experienced in...

Matthew Oram. The Trials of Psychedelic Therapy: LSD Psychotherapy in America.

The American Historical Review June 1, 2020 Claire D. Clark 2 citations

According to most histories, lysergic acid diethylamide (LSD) is a pharmaceutical whose therapeutic potential was dashed by controversies concerning countercultural drug use and covert government research. In contrast to familiar accounts of a rapid government crackdown on the drug, Matthew Oram’s The Trials of Psychedelic Therapy: LSD Psychotherapy in America describes the conclusion of...

Pharmacokinetics and subjective effects of 1P‐LSD in humans after oral and intravenous administration

Drug Testing and Analysis May 16, 2020 Christina Grumann, Kerstin Henkel, Simon D. Brandt et al. 23 citations

Abstract 1‐Propanoyl‐lysergic acid diethylamide (1P‐LSD) appeared as a non‐controlled alternative to LSD a few years ago. Although evidence is beginning to emerge from in vitro and animal studies that 1P‐LSD might serve as a prodrug for LSD, an equivalent evaluation in humans is unavailable. Controlled oral and intravenous self‐administrations of 100 μg 1P‐LSD hemitartrate are reported in two...

DOI: 10.1002/dta.2821 (opens in new tab) Pharmacokinetics Pharmacology Oral administration Administration probate law

Trends in LSD use among US adults: 2015-2018.

Drug and Alcohol Dependence May 15, 2020 R. Yockey, Rebecca A. Vidourek, Keith A. King 111 citations

BACKGROUND The recent use of LSD to treat severe psychological disorders in several clinical applications has proven effective in reducing symptoms and distressing events. Trend analyses are warranted to provide the most current data for clinical and health interventions. The purpose of this study was to examine trends in LSD use among adults in the United States. METHODS A secondary analysis...

Nothing Ventured, Nothing Gained: Regulations Cripple Potentially Life-Saving Research of Illicit Substances

ACS Chemical Neuroscience May 12, 2020 Kodye L. Abbott, Kristina Gill, Patrick Flannery et al. 7 citations

Modern day research, in an attempt to determine the potential therapeutic and adverse effects of illicit substances, is a growing field, but one that faces many regulatory challenges. Due to the potential abuse of illicit substances such as Cannabis, 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD) and psilocybin, regulations have been conceived with the intent of...

Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse

Neuropsychopharmacology May 5, 2020 Marcus W. Meinhardt, Cansu Güngör, Ivan Skorodumov et al. 66 citations

For most psychiatric disorders, including alcohol use disorder (AUD), approved pharmacological treatments are limited in their effectiveness, and new drugs that can easily be translated into the clinic are needed. Currently, great hope lies in the potential of psychedelics to effectively treat AUD. The primary hypothesis is that a single session of psychedelic-guided psychotherapy can restore...

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.

Psychopharmacology May 1, 2020 Toby Lea, Nicole Amada, Henrik Jungaberle et al.

The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. This paper examined subjective experiences of microdosing...

Identification and Analysis of LSD Derivatives in Illegal Products as Paper Sheet

Yakugaku Zasshi April 30, 2020 Rie Tanaka, Maiko Kawamura, Takashi Hakamatsuka et al. 15 citations

To prevent the abuse of new psychoactive substances (NPS), a total of 2372 substances and two plants are controlled as "Designated Substances" in Japan as of September 2019. Although the distribution of these substances has decreased for the past three years, newly-emerged NPS are still being found. In this study, we detected four lysergic acid diethylamide (LSD) derivatives as designer drugs...

Neural correlates of the LSD experience revealed by multimodal neuroimaging

UNC Libraries April 22, 2020 Peter J. Hellyer, Luke T. J. Williams, Ben Sessa et al. 1 citation

Lysergic acid diethylamide (LSD), the prototypical “psychedelic,” may be unique among psychoactive substances. In the decades that followed its discovery, the magnitude of its effect on science, the arts, and society was unprecedented. LSD produces profound, sometimes life-changing experiences in microgram doses, making it a particularly powerful scientific tool. Here we sought to examine its...

DOI: 10.17615/et5z-st50 (opens in new tab) Neuroimaging Cognitive psychology Cognition

Psychedelics for Psychiatric Disorders: More Research Needed

Psychiatric News April 13, 2020 Nick Zagorski

Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsychedelics for Psychiatric Disorders: More Research NeededNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:13 Apr 2020https://doi.org/10.1176/appi.pn.2020.4a14AbstractAPA’s Work Group on Biomarkers and Novel Treatments suggests that psychedelic drug trials need more standard...

Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1‐cyclopropanoyl‐d‐lysergic acid diethylamide (1CP‐LSD)

Drug Testing and Analysis March 16, 2020 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 38 citations

Abstract Lysergic acid diethylamide (LSD) is a prototypical serotonergic psychedelic drug and the subject of many clinical investigations. In recent years, a range of lysergamides has emerged with the production of some being inspired by the existing scientific literature. Others, for example various 1‐acyl substituted lysergamides, did not exist before their appearance as research chemicals....

The Novelty of Ayahuasca Scale and the prediction of intentions to use

Journal of Psychedelic Studies March 12, 2020 Brianna R. Altman, Maha N. Mian, Mitch Earleywine 4 citations

Abstract Objective Given the growing popularity of ayahuasca and other hallucinogens, we sought to identify related expectancies and their role in why people might use this psychoactive brew rather than classic hallucinogens like LSD or psilocybin. Method Experienced users (N = 139) completed an online survey about their use of hallucinogens (including ayahuasca), how their ayahuasca...

Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression

ACS Chemical Neuroscience March 5, 2020 Meghan Hibicke, Alexus N. Landry, Hannah M. Kramer et al. 211 citations

Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more months after only one or two treatments. Another hallucinogenic drug, esketamine, has recently been U.S. Food and Drug Administration (FDA)-approved as a rapid-acting antidepressant. The mechanistic basis for the antidepressant effects of psilocybin and ketamine appear to be conserved. The efficacy of...

Psychedelics and dissociative substances

March 1, 2020 Adam Winstock, James W. Rucker 29 citations

Abstract Psychedelics and hallucinogens represent some of the most commonly used drugs in the world, with a history of use steeped in spirituality, counter-culture, and more recently latent therapeutic potential. Sharing a common mechanism of action at the 5-HT2a receptor, drugs such as lysergic acid diethylamide (LSD) and psilocybin, while they can rarely induce significant short-term...

NBOMes–Highly Potent and Toxic Alternatives of LSD

Frontiers in Neuroscience February 26, 2020 Monika Kacela, Piotr Adamowicz, Jolanta B. Zawilska 79 citations

Recently, a new class of psychedelic compounds named NBOMe (or 25X-NBOMe) has appeared on the illegal drug market. NBOMes are analogs of the 2C family of phenethylamine drugs, originally synthesized by Alexander Shulgin, that contain a N-(2-methoxy)benzyl substituent. The most frequently reported drugs from this group are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. NBOMe compounds are ultrapotent and...